Aptose to Hold Corporate Update Friday, June 11th

- May 27th, 2021

Aptose Biosciences Inc. a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11 th at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress. The event will include an up-to-date review of clinical data …

Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS

Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at EHA2021 Virtual Congress

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update for the investment community on Friday, June 11 th at 8:00 AM ET, in conjunction with participation at the EHA2021 Virtual Congress. The event will include an up-to-date review of clinical data available for Aptose’s clinical programs: luxeptinib (CG-806), Aptose’s oral, first-in-class FLT3 and BTK kinase inhibitor in two Phase 1 ab trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies; and APTO-253, a first-in-class small molecule MYC repressor in a Phase 1 ab trial in patients with relapsed or refractory AML or high risk myelodysplastic syndromes (MDS).

Aptose Corporate Update Details 

Date & Time: Friday, June 11th, 8:00 AM ET
Participant Webcast Link : LINK
Participant Dial-in:

Toll Free:

1-877-407-9039
Toll/International : 1-201-689-8470
Conference ID: 13719895

The slides will be available on Aptose’s website here and a recording of the presentation will be archived shortly after the conclusion of the event.

Early clinical data for luxeptinib (CG-806) and APTO-253 also will be presented in posters at the EHA2021 Virtual Congress , to be held virtually June 9 – 17, 2021. All e-posters will be made available in the Virtual Congress platform on Friday, June 11 at 09:00 CEST / 03:00 ET. The posters also will be available on the presentations page of Aptose website here .

Poster Presentation Details

Title: A Phase 1a/b dose escalation study of the mutation agnostic BTK/FLT3 inhibitor luxeptinib (CG-806) in patients with relapsed or refractory B cell malignancies
Topic: Chronic lymphocytic leukemia and related disorders – Clinical
Final Abstract Code: EP643
Poster Date & Time: Friday, June 11 at 09:00 CEST
Title: A Phase 1a/b dose escalation study of the MYC repressor APTO-253 in patients with relapsed or refractory AML or high-risk MDS
Topic: Acute myeloid leukemia – Clinical
Final Abstract Code: EP452
Poster Date & Time: Friday, June 11 at 09:00 CEST

Abstract Only

Title: A Phase 1a/b dose escalation study of the mutation agnostic BTK/FLT3 inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia
Topic: Acute myeloid leukemia – Clinical
Final Abstract Code: PB1391

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies. The first investigational product, luxeptinib, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML). The second investigational product, APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).

For further information, please contact:

Aptose Biosciences Inc. LifeSci Advisors, LLC
Susan Pietropaolo Dan Ferry, Managing Director
Investor Relations 617-535-7746
201-923-2049 Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply